Your location: Skip Navigation LinksHome > News > UV Flu Technologies Commences Shipments From China of ViraTech UV-400 Air Purifier

UV Flu Technologies Commences Shipments From China of ViraTech UV-400 Air Purifier

    5/18/2010 9:52:00 AM    ReadCount:631

CENTERVILLE, MA, May 17, 2010 (MARKETWIRE via COMTEX) -- UV Flu Technologies, Inc. (the "Company") is pleased to announce that the latest production order of the Company's flagship Indoor Air Quality ("IAQ") product known as the ViraTech UV-400 Air Purifier, has been completed and the first containerized shipment from China will commence shortly.

The latest production run incorporates additional features combining the patented UV bacteria killing technology which has been cleared by the FDA for use as a medical device with a newly developed Catalytic UV Technology, and also incorporates an activated carbon screen.

"We believe the UV-400, with these new product improvements combined with its patented UV technology, is the most effective, bacteria-killing air purifier in the world today," said Jack Lennon, President of UV Flu Technologies, Inc. "We have worked diligently with our engineers in China to improve the effectiveness of our product, and provide even more value for our customers. We are getting requests for information on a daily basis from countries all over the world, particularly from hospitals."

Mr. Lennon continued, "Secondary infections in hospitals are a problem all over the world, and our product can help immeasurably in combating these issues. Nursing homes, medical waiting rooms, and even hotels that cater to hospital patients and their families are perfect application examples for our product. We further believe that conference rooms, locker rooms and educational facilities from pre-schools on up, along with government and military installations could all benefit tremendously."

The Company plans to announce delivery and commercial availability of the newly updated product shortly. Those interested in the product, or wishing to pre-order are invited to contact the distributor, Puravair LLC at 1-866-6-PURAVAIR or by email at

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

About UV Flu Technologies, Inc.UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


UV Flu Technologies, Inc. -----------------------------

John J. Lennon, President & CEO